 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
pemigatinib receiv fda approv cca week
ahead schedul await management commentari price
launch detail broadli believ earli approv bode
well regulatori review time line tafasitamab
pdufa date earn present next
catalyst
pemigatinib approv earli cholangiocarcinoma fda approv
fgfr inhibitor pemigatinib pemazyr treatment
cholangiocarcinoma cca fusion rearrang cca
cancer bile duct fusions/rearrang typic occur
intrahepat cca icca estim incid icca case
relat mutat patient approv come week
ahead program pdufa date earli approv
present signific fundament valuat upsid current estim
current forecast non risk-adjust cca revenu
believ earli approv bode well on-tim regulatori review
approv antibodi tafasitamab r/r dlbcl pdufa date
indic fda review process may yet
significantli impact relat delay current model
month delay approv tafasitamab launch
conservat account potenti disrupt fda time line present
on-tim approv late launch present minim
upsid current valuat believ would posit
sentiment driver given tafasitamab present key late-stag program
management plan hold call discuss pemazyr approv monday
et see detail look forward learn price
launch logist given statu phii pemigatinib bladder
phiii ruxcovid studi initi associ cytokin storm
also announc friday phiii random double-blind placebo-
control studi jakafi soc initi patient age
cytokin storm relat infect studi expect enrol
patient global novarti cover mark purcel
sponsor studi ex-u respect primari endpoint
studi composit measur proport patient die
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
requir mechan ventil requir icu care day follow
treatment note plan ruxcovid studi first announc
acknowledg mechanist rational pursu
evalu jakafi covid associ cytokin storm well encourag
earli report anecdot use current valu jakafi
challeng understand precis account
price perform april vs xbi appear us
increas share relat ruxcovid studi
believ run-up persist could creat challeng set-up
head earn particularli quarterli earn note
advers relat impact jakafi expect commerci perform
and/or data regulatori catalyst
recap catalyst investor recent inquir
priorit catalyst anticip throughout market volatil
make challeng predict specif upside/downsid catalyst
qualit assign high/modest/low rank base current view
next key catalyst
ruxolitinib cream nda submiss ruxolitinib cream mild-to-moder ad
submiss antibodi tafasitamab r/r dlbcl ema
pdufa date tafasitamab r/r dlbcl
phiii studi jakafi steroid-refractori chronic gvhd cgvhd
initi phiii studi evalu jakafi myelofibrosi mf
proof-of-concept data jakafi pim myelofibrosi mf
initi bioequival data once-a-day ruxolitinib
updat phii data pemigatinib bladder cancer
updat phii data parsaclisib non-hodgkin lymphoma nhl
phii data antibodi anal cancer
initi clinic data oral inhibitor solid tumor
phib data first-mind studi evalu tafasitamab dlbcl
valuat methodolog risk
deriv price target discount cash flow analysi factor explicit
revenu project use discount rate termin
risk upsid
greater pipelin realiz base case project includ
risk downsid
long-term jakafi sale perform expect
regulatori failur ruxolitinib cream ad slow launch assum
clinic and/or regulatori failur tafasitamab
failur and/or minim success earlier-stag program like
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report vikram
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import regulatori disclosur subject compani
march benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur alector inc amgen inc aprea
within last month receiv compens invest bank servic alector inc
next month expect receiv intend seek compens invest bank servic akebia
within last month receiv compens product servic invest bank servic amgen inc
within last month provid provid invest bank servic invest bank client relationship
follow compani alector inc amgen inc
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amgen inc beigen ltd biogen inc biomarin
 co llc make market secur alector inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
use rel rate system use term overweight equal-weight not-rat underweight see definit morgan
stanley assign rate buy hold sell stock cover overweight equal-weight not-rat underweight equival
buy hold sell investor care read definit rate use morgan stanley research addit sinc morgan stanley research
contain complet inform concern analyst view investor care read morgan stanley research entireti infer
content rate alon case rate research use reli upon invest advic investor decis buy sell
stock depend individu circumst investor exist hold consider
march
stock rate describ appli fundament equiti research appli debt research produc firm
disclosur purpos accord finra requir includ categori head buy hold sell alongsid rate
overweight equal-weight not-rat underweight assign rate buy hold sell stock cover overweight
equal-weight not-rat underweight equival buy hold sell repres recommend rel weight see definit
satisfi regulatori requir correspond overweight posit stock rate buy recommend correspond equal-weight
not-rat hold underweight sell recommend respect
data includ common stock adr current assign rate invest bank client compani receiv invest
bank compens last month due round decim percentag provid total column may add exactli
overweight stock total return expect exceed averag total return analyst industri industri team coverag univers
risk-adjust basi next month
equal-weight stock total return expect line averag total return analyst industri industri team coverag univers
risk-adjust basi next month
not-rat nr current analyst adequ convict stock total return rel averag total return analyst
industri industri team coverag univers risk-adjust basi next month
underweight stock total return expect averag total return analyst industri industri team coverag univers
risk-adjust basi next month
unless otherwis specifi time frame price target includ morgan stanley research month
attract analyst expect perform industri coverag univers next month attract vs relev broad
market benchmark indic
in-lin analyst expect perform industri coverag univers next month line relev broad market
benchmark indic
cautiou analyst view perform industri coverag univers next month caution vs relev broad market
benchmark indic
benchmark region follow north america latin america relev countri index latin america index europ
europ japan topix asia relev countri index sub-region index ac asia pacif ex japan index
stock price price target rate histori rate definit
import disclosur morgan stanley smith barney llc custom
